Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Friday, August 10th at 10:00 am ET
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the second quarter of 2018. The Company will host a call to update investors on recent clinical developments and quarter financial results on Friday, August 10th at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-407-9210 (toll-free domestic) or 201-689-8049 (International) or via webcast http://www.investorcalendar.com/event/35041.
“The second quarter was marked by continued progress in our clinical, pre-clinical and corporate initiatives,” stated Carsten Thiel, Ph.D., Abeona’s CEO. “The strength of our lead programs, which continue to demonstrate robust and durable clinical effects, is underscored by the achievement of additional regulatory designations and the recent appointment of key executives and Board members. Notably, the opening of our in-house GMP manufacturing facility in Cleveland reinforces Abeona’s ongoing commitment to transforming patients’ lives and bolsters our position for commercial readiness.”
2nd Quarter Summary Financial Results:
- Cash position: Cash, cash equivalents and marketable securities as of June 30, 2018 were $120 million, compared to $132 million as of March 31, 2018.
- Revenues: Revenues were $819 thousand for the second quarter of 2018, compared to $217 thousand in the second quarter of 2017. A portion of the increased quarterly revenues consisted of the recognition of Foundation grants that were announced during the fourth quarter of 2017. A portion of the grants were received in the second quarter of 2018, and the amount recognized is matched against corresponding expenditures for drug manufacture and clinical readiness. Additional revenues consisted of royalties from marketed products, primarily MuGard®.
- Loss per share: Loss per share was $0.25 for the second quarter of 2018, compared to a loss per share of $0.21 in the comparable period in 2017.
Abeona Recent Highlights:
- July 26, 2018: Announced Leadership Appointments with Max Colao as Chief Commercial Officer
- May 31, 2018: Announced Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
- May 18, 2018: Reported Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
• ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes
• 11 subjects enrolled through > 4,200 days cumulative follow up
- May 17, 2018: Reported Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
• Phase 1/2 study update results confirm EB-101 is safe and well-tolerated, with durable efficacy throughout various timepoints post-administration
• Collagen VII (C7) expression: C7 and morphologically normal NC2 reactive anchoring fibrils were observed as early as one month in EB-101 treated wounds and have remained up to three years post-administration.
• Wound healing, defined as >50% closure after EB-101 administration, was observed in:
--- 100% (42/42 treated wounds, n=7 subjects) at 3 months;
--- 90% (38/42 treated wounds, n=7 subjects) at 6 months;
--- 67% (24/36 treated wounds, n=6 subjects) at 12 months;
--- 88% (21/24 treated wounds, n=4 subjects) at 24 months; and
--- 100% (6/6 treated wounds, n=1 subject) at 36 months post-administration.
- May 14, 2018: Announced Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
- April 23, 2018: Announced FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
- April 20, 2018: Announced EMA Grants Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
- April 2, 2018: Announced Appointment of Carsten Thiel, Ph.D., as Chief Executive Officer
“As we advance towards becoming a key player in the development of novel breakthrough gene and cell therapies for rare genetic diseases, 2018 continues to be a year of execution for Abeona,” stated Steven H. Rouhandeh, Abeona’s Executive Chairman.
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.
SVP, Finance & Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4707
Berry & Company Public Relations
+1 (212) 253-8881
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our advancement towards becoming a key player in the development of novel breakthrough gene and cell therapies for rare genetic diseases and that 2018 continues to be a year of execution. We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support our approach for intravenous delivery for subjects with Sanfilippo syndromes, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot Announces Appointment of General Counsel17.6.2019 22:29:00 CEST | Pressemelding
BALTIMORE, June 17, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (Nasdaq: WSC) today announced the appointment of Mr. Hezron Timothy Lopez to serve as the Company’s Vice President, General Counsel & Corporate Secretary, effective June 17, 2019. Mr. Lopez joins WillScot after having served from 2012 to 2018 as Senior Vice President, General Counsel and Corporate Secretary of Herman Miller, Inc., a Nasdaq-listed manufacturer of home and office furniture. From 2008 to 2012, Mr. Lopez served as Associate General Counsel and Head of Merger & Acquisition, Commercial and International for A. O. Smith Corporation, a manufacturer of water heating equipment and water treatment products. About WillScot Corporation Headquartered in Baltimore, Maryland, WillScot (Nasdaq: WSC) is the public holding company for the Williams Scotsman family of companies and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North Americ
Cineworld Group and Cinionic Strike 1,000+ Unit Deal to Roll Out Acclaimed Barco Laser Projectors to Theaters Worldwide17.6.2019 18:05:00 CEST | Pressemelding
Cineworld embarks on global renewal with Cinionic, powered by award-winning projection portfolio and enhanced services KORTRIJK, Belgium, June 17, 2019 (GLOBE NEWSWIRE) -- Cinionic, the Barco, CGS, and ALPD cinema joint venture providing a new visual standard with enhanced services and technology solutions, announces a significant expansion in its relationship with one of the world’s largest theater chains, Cineworld Group plc (LON:CINE), to continue delivering an elevated movie-going experience for audiences worldwide. Cinionic will illuminate Cineworld Group operated theaters in the U.S., EU and UK with enhanced services and award-winning portfolio of Barco laser projectors, including the newly launched Barco Series 4. Over the next 18 months, Cineworld will upgrade and deploy over 1,000 projectors worldwide with Barco Laser solutions to deliver a new visual standard in cinema, supported by Barco Alchemy media servers and maintained for the next decade through Cinionic’s enhanced ser
Rock Tech Engages KBM Resources Group for LiDAR Survey at Georgia Lake17.6.2019 14:15:00 CEST | Pressemelding
VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) -- Rock Tech Lithium Inc. (the "Company" or “Rock Tech”) (TSX-V: RCK; Frankfurt: RJIB) is pleased to announce that it has engaged KBM Resources Group (“KBM”) to complete a LiDAR and high-resolution imagery survey at its 100%-owned Georgia Lake lithium project in Ontario, Canada. The aerial acquisition of LiDAR and digital photography will cover the Nama Creek main zone and adjacent areas of the Georgia Lake lithium project. The LiDAR survey, with a relatively high resolution of 10 laser points per square metre and an absolute accuracy of 10 cm vertical and 20 cm horizontal, will produce LAS files with classified ground points including a bare earth model and georeferenced orthoimagery. “The ideal time to fly this survey is after the snow melt and before leaf-out,” commented Martin Stephan, Rock Tech’s Chief Executive Officer. “These conditions, combined with a favourable regional weather forecast, shall make for a successful L
Carpenter Technology and Israel Aerospace Industries Announce Collaboration to Produce Commercial Aircraft Additive Parts17.6.2019 14:00:00 CEST | Pressemelding
Le Bourget, FRANCE, June 17, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) and Israel Aerospace Industries (IAI) today announced their collaboration to produce additively manufactured components for a serial production commercial aircraft. This collaboration will result in IAI’s first metallic additively-produced parts, which are expected to provide significant manufacturing benefits and lay the groundwork for future design improvements and enhancements. IAI is working closely with Israel’s Civil Aviation Authority for approval of the parts, which when accomplished will represent the first time this technology has been approved for commercial use in Israel. Carpenter Technology, through its Carpenter Additive business unit, is producing the parts and providing supporting information to assist with their approval. “Together, Carpenter Additive and IAI are pioneering the use of this technology for new platforms and applications,” said Marshall Akins, Carpenter Tec
Major HAProxy Releases Increase Support for Cloud-Native and Containerized Application Architectures17.6.2019 14:00:00 CEST | Pressemelding
Key Community Releases Include HAProxy 2.0, HAProxy Data Plane API and HAProxy Kubernetes Ingress Controller WALTHAM, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- HAProxy Technologies, provider of the world’s fastest and most widely-used software load balancer, today announced that the HAProxy community has released HAProxy 2.0 and several other key products that make it easier to extend, configure and manage HAProxy in cloud-native and containerized environments. The company also announced its inaugural community user conference, HAProxyConf 2019, which will take place in Amsterdam, Netherlands on November 12th and 13th, 2019. “The release of HAProxy 2.0 along with the new HAProxy Data Plane API and HAProxy Kubernetes Ingress Controller mark the culmination of a significant re-architecture of HAProxy to add the flexibility and features needed to optimize support for modern application architectures,” said Willy Tarreau, HAProxy community lead and HAProxy Technologies CTO. “I am extremely
Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders17.6.2019 12:55:00 CEST | Pressemelding
BROOKFIELD, NEWS, June 17, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM, Euronext: BAMA) today announced that at the company’s annual and special meeting of shareholders held on June 14, 2019 in Toronto, over 85% of Class A Limited Voting Shares (“Class A Shares”) voted in favour of a new management share option plan. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares (“Class B Shares”) were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 731,503,129 99.60 2,926,448 0.40 Angela F. Braly 730,750,957 99.50 3,67